Omnipathology Solutions Medical Corporation

Omnipathology Solutions Medical Corporation was paid $6.20M by Medicaid between Jan 2020 and Nov 2024, across 13 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 80% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#99 of 561

Median peer was paid$222K

This provider vs. median28×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	8,059	$461K
2021	43,234	$1.54M
2022	71,188	$3.05M
2023	18,057	$1.12M
2024incomplete	1,930	$24K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	80%	78,831	43,296	$4.98M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	8.4%	42,413	24,478	$519K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	4.6%	2,093	1,620	$286K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	1.9%	4,917	1,917	$115K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	1.6%	1,934	1,310	$98K
88305	Level IV - Surgical pathology, gross and microscopic examination	1.3%	3,911	3,780	$82K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	3,993	1,735	$62K
88312		<1%	2,149	2,140	$27K
88313		<1%	2,174	2,166	$26K
88342		<1%	14	13	$309.50
87625		<1%	13	12	$217.72
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	13	12	$209.16

1 more codes

87591

Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe

<1%

13

$208.56

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialDAVID, CLAIRE (PRACTICE ADMINISTRATOR)